June 02, 2026 —
The U.S. FDA has issued new draft guidance intended to help accelerate the development of cell and gene therapies by allowing sponsors to make greater use of existing scientific and regulatory knowledge. The guidance focuses on how developers may leverage publicly available information and established platform knowledge to support regulatory submissions for human gene therapy products, including genome editing therapies in human somatic cells.
The draft guidance is designed to reduce redundant testing while maintaining rigorous safety, quality, and efficacy standards. When finalized, it will outline how sponsors can use prior knowledge across multiple areas of development, including chemistry, manufacturing and controls, nonclinical studies, and clinical information. The goal is to help companies build more efficient development programs, particularly for rare and life-threatening diseases where patients often have limited or no treatment options.
The FDA emphasized that leveraging prior knowledge does not mean lowering regulatory standards. Sponsors will still need to provide a scientific rationale showing that the information they are using is applicable to their specific product, platform, disease context, and development strategy. This may be especially important for gene therapy and genome editing programs where delivery systems, editing tools, manufacturing platforms, and safety profiles can vary significantly across products.
The guidance also complements other recent FDA initiatives in the cell and gene therapy field. For genome editing therapies, it is intended to work alongside the agency’s Plausible Mechanism Framework and its recent draft guidance on using next-generation sequencing to assess off-target editing risks. Together, these efforts aim to provide a clearer science-based path for developers while supporting patient safety.
FDA officials encouraged sponsors to engage with the agency early in development, including through INTERACT and pre-IND meetings, to discuss how prior knowledge may be applied to their specific programs. Early engagement may help clarify what data can be leveraged, what additional studies are still needed, and how to design more efficient development packages.
The draft guidance is open for public comment, with comments due within 90 days of publication in the Federal Register. After reviewing feedback, the FDA will consider revisions before finalizing the guidance.
For the cell and gene therapy industry, the draft guidance reflects a broader regulatory shift toward platform-aware development. As more companies use related vectors, genome editing systems, delivery technologies, and manufacturing processes across multiple programs, the ability to leverage prior knowledge could help lower development burden, reduce timelines, and improve access to advanced therapies for patients with serious diseases.
